Clinical trials depend upon the participation of individuals who volunteer sometimes to access medicines but often to help science advance for the benefit of future patients; each trial, therefore, should be valuable and important. But how can one know if a trial will be important or even informative before results are published? In this proposal, the team will investigate the ethical and practical implications of including an assessment of scientific value and informativeness in decisions regarding the initiation or continuation of clinical trials.
Preventing the initiation of, and deprioritizing the continuation of, uninformative clinical trials
Brigham and Women's Hospital